IL6 and melanoma: On the other hand, it has been reported that elevations in the pre-therapy serum concentrations of the cytokines IFN-γ (P < 0.0001), IL-6 (P < 0.0007), and IL-10 (P < 0.0001) are predictive of treatment efficacy in patients with advanced melanoma receiving nivolumab (42).